Common Contracts
4 similar Underwriting Agreement contracts by Alexion Pharmaceuticals Inc, Atheros Communications Inc, Myriad Genetics Inc, Vicuron Pharmaceuticals Inc
5,000,000 Shares ALEXION PHARMACEUTICALS, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • July 21st, 2004 • Alexion Pharmaceuticals Inc • Pharmaceutical preparations • New York
Alexion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) 5,000,000 shares of its Common Stock, par value $0.0001 per share (the “Firm Shares”). The Company also proposes to issue and sell to the several Underwriters not more than an additional 500,000 shares of its Common Stock, par value $0.0001 per share (the “Additional Shares”), if and to the extent that you, as Managers of the offering, shall have determined to exercise, on behalf of the Underwriters, the right to purchase such shares of common stock granted to the Underwriters in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the “Shares.” The shares of Common Stock, par value $0.0001 per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the “Common Stock.”
3,400,000 Shares Myriad Genetics, Inc. COMMON STOCK, $0.01 par value UNDERWRITING AGREEMENTUnderwriting Agreement • June 4th, 2004 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
Myriad Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Morgan Stanley & Co. Incorporated (the “Underwriter”) 3,400,000 shares of its common stock, $0.01 par value per share (the “Firm Shares”). The Company also proposes to issue and sell to the Underwriter not more than an additional 510,000 shares of its common stock, $0.01 par value per share (the “Additional Shares”), if and to the extent that you shall have determined to exercise the right to purchase such shares of common stock granted to you in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the “Shares.” The shares of common stock, $0.01 par value per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the “Common Stock.”
ATHEROS COMMUNICATIONS, INC. COMMON STOCK ($0.0005 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • January 16th, 2004 • Atheros Communications Inc • Semiconductors & related devices • New York
6,000,000 Shares VICURON PHARMACEUTICALS INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • July 18th, 2003 • Vicuron Pharmaceuticals Inc • Pharmaceutical preparations • New York
VICURON PHARMACEUTICALS INC., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I attached hereto (the “Underwriters”) 6,000,000 shares of its common stock, $0.001 par value per share (the “Firm Shares”). The Company also proposes to issue and sell to the several Underwriters not more than an additional 900,000 shares of its Common Stock, $0.001 par value per share (the “Additional Shares”), if and to the extent that you, as managers of the offering, shall have determined to exercise, on behalf of the Underwriters, the right to purchase such shares of common stock granted to the Underwriters in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the “Shares.” The shares of common stock, $0.001 par value per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the “Common Stock.”
